This page uses content from Wikipedia and is licensed under CC BY-SA.

Ficlatuzumab

Ficlatuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetHGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6446H9954N1718O2026S46
Molar mass145.41 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]

Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[2]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
  2. ^ "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012